Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Molecule That Gives Energy-Burning Brown Fat its Identity Could Lead to Drugs for Obesity

By Salk Institute | March 13, 2018

Infrared images indicate the much warmer temperatures of a normal mouse (left) compared to a mouse unable to make ERR gamma (right).

While most fat cells in the human body store energy, everyone has a small subset of brown fat cells that do the opposite–burn energy and generate heat. Now, Salk researchers have discovered how the molecule ERRγ gives this “healthier” brown fat its energy-expending identity, making those cells ready to warm you up when you step into the cold, and potentially offering a new therapeutic target for diseases related to obesity. The paper appears in Cell Reports on March 13, 2018.

“This not only advances our understanding of how the body responds to cold, but could lead to new ways to control the amount of brown fat in the body, which has links to obesity, diabetes and fatty liver disease,” says senior author Ronald Evans, Howard Hughes Medical Institute investigator and holder of Salk’s March of Dimes Chair in Molecular and Developmental Biology.

Until about a decade ago, scientists thought that only babies–who can’t yet shiver to warm up–had brown fat in their bodies. Studies have since shown that adults also have brown fat, albeit at much lower levels, and people with lower body mass indexes (BMIs) tend to have more of it. At a cellular level, brown fat cells are crammed full of energy-generating mitochondria, which give the cells their brown color.

In the new work, Evans’ group focused on estrogen-related receptor gamma (ERRγ), a gene that is active at high levels in brown fat cells.

“We were interested in what maintains brown fat, even when we’re not exposed to cold all the time,” says Maryam Ahmadian, a Salk research associate and first author of the new paper.

The team found that brown fat cells express the ERRγ gene all the time (not just in response to cold) and that white fat cells do not express the gene at all. And by studying mice lacking the gene for ERRγ (and therefore unable to make the ERRy molecule), the team observed that all brown fat cells resembled white cells in these mice. Additionally, the animals were unable to maintain their body temperature when exposed to cold temperatures. While 80 percent of normal mice are able to handle a temperature drop, all mice lacking ERRγ did not tolerate the cold. However, there was no difference in the metabolism or weight of the mice. Together, the experiments reveal that ERRγ is key to helping brown fat maintain its identity and its ability to respond to cold.

Since the ERRγ gene codes for a protein that can travel into the cell nucleus and directly control the expression of other genes, the team also probed which genes were mediated by ERRγ in brown fat cells. They pinpointed a number of genes already known to be important in brown fat, but which hadn’t been specifically linked to ERRγ in the past.

“We uncovered the factors that are both involved in protection against the cold and underpin brown fat identity,” says Michael Downes, a Salk senior scientist and co-senior author of the paper.

The group is planning future studies that look at the effect of activating ERRγ in white fat cells–which they suspect could make some white fat resemble brown fat, and potentially help treat obesity and diabetes. They also want to study whether the role of ERRγ in the brown fat of humans is the same as what they’ve observed in mice.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE